期刊文献+

注射用磷酸肌酸钠在应用表阿霉素化疗中心脏毒性保护作用 被引量:4

Protective Action of Creatine Phosphate Sodium for Reducing Cardiac Toxicity Induced by Epirubicin
暂未订购
导出
摘要 目的探讨注射用磷酸肌酸钠能否减轻表阿霉素化疗引起的心脏毒性。方法治疗组40例于化疗的同时,应用注射用磷酸肌酸钠静滴,并用含表阿霉素的方案联合化疗;对照组40例单用化疗。结果治疗组与对照组比较,总有效率为35.0%,对照组为32.5%(P>0.05);两组治疗后心脏节律异常率为12.5%VS 50.0%(P<0.05);心功能损害发生率为7.5%VS 32.5%;治疗组治疗后左室射血分数高于对照组(P>0.05)。结论注射用磷酸肌酸钠不影响抗肿瘤效果,能降低表阿霉素方案化疗所致心脏毒性的发生率,改善化疗患者的生活质量。 Objective To discuss whether creatine phosphate sodium for injection in reducing cardiac toxicity induced by epirubicin.Methods The treatment group(40 cases) and the control group(40 cases) were treated with adriamycin.At the same time,the treatment group were given creatine phosphate sodium for injection.Results The total effective rate of the treatment group and the control group were 35% and 32.5%,respectively(P0.05);the incidence rate of heart rhythm abnormality were 12.5% and 50.0%,respectively(P0.05);the incidence rate of cardiac dysfunction were 7.5% and 32.5%,respectively;left ventricular ejection fraction of the treatment group was higher than that of the control group(P0.05).Conclusion Creatine phosphate sodium for injection could reduce the incidence of cardiac toxicity induced by epirubicin and improve the quality of life of the patients without weakening therapeutic effect.
机构地区 大庆油田总医院
出处 《黑龙江医学》 2011年第10期772-774,共3页 Heilongjiang Medical Journal
关键词 注射用磷酸肌酸钠 表阿毒素 心脏毒性 生活质量 Creatine phosphate Epirubicin Cardiac toxicity
  • 相关文献

参考文献9

  • 1徐叔云.巾华临床药物学[M].北京:人民卫生出版社,2003:1443-1448.
  • 2Yeh E T,Tong A T,Lenihan D J,et al.Cardiovascular complications of cancer therapy diagnosis,pathogenesis,and management[J].Criculation,2004,109:3 122-3 131.
  • 3Dazzi H,Kaudmann K,Follath F.Anthracyline-induced acute cardiotoxicity in adults treatd for leukemia.Analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukemia at the University Hospital of Zurich,Switzerland between 1990 and 1996[J].Ann Oncol,2000,12(7):963-966.
  • 4Richardson DR,Persson L,Xu X.Molecular pharmacology of the interaction of anthracyclines with iron[J].Mol Pharmacol,2005,9:466.
  • 5Bertinchant JP,Polge A,Robert E,et al.Evaluation of cardiac troponin l and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats.and their relationship with echocardiographic and histological findings[J].Clin Chem Acta,2003,329(1-2):39-51.
  • 6Mohammad G l,Al-Menshawy A M,Abd El-Hakeem E E,et al.The value of biochemical markers in evaluation of myocardial damage in children[J].Eng J Anaesth,2003,19(1):1-8.
  • 7闫爱霞,沈文莉.磷酸肌酸钠治疗新生儿缺氧缺血性心肌损害疗效观察[J].临床军医杂志,2009,37(3):396-397. 被引量:18
  • 8沈炳权,陈明,朱霞,张丽.磷酸肌酸钠对慢性心衰患者心功能的影响[J].浙江中西医结合杂志,2008,18(1):15-16. 被引量:12
  • 9吴丽燕,黄辉文,郭梁.磷酸肌酸治疗新生儿缺氧缺血性脑病合并心肌损害的临床研究[J].国际医药卫生导报,2008,14(19):10-13. 被引量:11

二级参考文献15

共引文献30

同被引文献23

  • 1张小玲,陈真云,盛修贵.外阴阴道黑色素瘤研究进展[J].实用癌症杂志,2006,21(1):110-112. 被引量:1
  • 2Mousavi AS; Fakor F, Nazari Z, et al. Primary malignant melanorma of the uterine cervix : case report and review of the literature [ J ]. JLow Genit Tract Dis ,2006, 10 : 258-263.
  • 3Eggermont AM, Suciu S, Mackie R, et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage Ⅱ b/Ⅲ melanoma ( EORTC 18952 ) : random- ized controlled trial [ J ]. Lancet,2005,366 : 1189-1196.
  • 4Bajetta E. Adjuvant use of interferon alpha 2b is not justified in pa- tients with stage lib/Ill melanoma [ J ]. Nat Clin Pract Ortcol, 2008, 5(1) :4-5.
  • 5Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med ,2007, 13 : 54-61.
  • 6Casares N, Pequiqnot MO, Tesniere A, et al. Caspase-dependent im- munogenieity of doxorubicin-induced tumor cell deatla. J Eep Med, 2005,202(12) : 1691-1701.
  • 7Hauschild A. Adjuvant interferon alia for melanoma: new evidence- based treatment recommendations[ J]. Curr Oncol, 2009,16(3) :3-6.
  • 8Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and man- agement of toxicities associated with high-dose interferon alfa-2b ther- apy[ J]. J Clin Oncol, 2002, 20(17) :3703-3718.
  • 9Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study-United Kingdom Coordina- ting Committee on Cancer Research randomized study of adjuvant low- dose extended-duration interferon alfa-2a in high-risk resected malig- nant melanoma[ J]. J Clin 0ncol,2004,22( 1 ) :53-61.
  • 10Kleeberg UR, Suciu S, Brocker EB, et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trail, rlFN-alpha2b versus rIFN- gamma versus ISCADOR M versus observation after sur- gery in melanoma patients with either high-risk primary ( thickness > 3ram) or regional lymph node metastasis [ J ]. Eur J Cancer,2004,40 (3) :390-402.

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部